Login
$MRNA
$213.17 -$2.10 (0.98%) After hours

$MRNA 8-K SEC Filings

Filed On Filing
13 Nov 2026 8-K: Departure/Election of Directors or Officers; Compensation
06 Nov 2026 8-K: Results of Operations and Financial Condition

Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38

30 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Jerh Collins to Retire Following Four Years of Leadership at Moderna

01 Sep 2026 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more

INDENTURE dated as of September 1, 2026 between MODERNA, INC., a Delaware corporation, as issuer (the “Company,” as more fully set forth in Section 1.01) and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, ...

31 Jul 2026 8-K: Results of Operations and Financial Condition

Reports second quarter revenue of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(1.97)

08 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Former Biogen Chief Financial Officer brings more than 35 years of financial leadership and public company experience

11 May 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Section 8 of Article VI of the Second Amended and Restated By-laws of the Corporation (the “By-laws”) is hereby amended and restated in its entirety as follows:

01 May 2026 8-K: Results of Operations and Financial Condition

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international markets

05 Mar 2026 8-K: Entry into a Material Definitive Agreement

On March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbutus Biopharma Corporation (“Arbutus”), Genevant Sciences GmbH (“Genevant” and, together with Arbutu...

13 Feb 2026 8-K: Results of Operations and Financial Condition

Reports fourth quarter revenue of $0.7 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.11)

11 Feb 2026 8-K: Regulation FD Disclosure; Other Events

Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010

12 Jan 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings Call

05 Jan 2026 8-K: Regulation FD Disclosure

Moderna navigated a difficult environment in the U.S. in 2025. In this complex context, we focused on what we could control: operational execution, scientific progress and disciplined financial management. Our Mission—to deliver the grea...

24 Nov 2025 8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation

CERTAIN SUBSIDIARIES OF THE BORROWERFROM TIME TO TIME PARTY HERETO,as Guarantor Subsidiaries,

20 Nov 2025 8-K: Regulation FD Disclosure

Announces three-year business strategy and commercial growth drivers, targeting up to 10% revenue growth in 2026

13 Nov 2025 8-K: Submission of Matters to a Vote of Security Holders

On November 12, 2025, Moderna, Inc. (the “Company”) held its previously announced Special Meeting of Shareholders (the “Special Meeting”), at which a quorum was present. The final voting results for the Special Meeting are as follows:

06 Nov 2025 8-K: Results of Operations and Financial Condition

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)

01 Aug 2025 8-K: Results of Operations and Financial Condition

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)

05 May 2025 8-K: Submission of Matters to a Vote of Security Holders

On April 30, 2025, the Company held its previously announced 2025 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present. The final voting results for the Annual Meeting are as follows:

01 May 2025 8-K: Results of Operations and Financial Condition

Reports first quarter revenues of $0.1 billion, GAAP net loss of $(1.0) billion and GAAP EPS of $(2.52)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support